Skip to main content
Erschienen in: Cancer and Metastasis Reviews 3/2019

31.10.2019

Differential roles of protease isoforms in the tumor microenvironment

verfasst von: Chamikara Liyanage, Achala Fernando, Jyotsna Batra

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Alternative splicing of precursor mRNA is a key mediator of gene expression regulation leading to greater diversity of the proteome in complex organisms. Systematic sequencing of the human genome and transcriptome has led to our understanding of how alternative splicing of critical genes leads to multiple pathological conditions such as cancer. For many years, proteases were known only for their roles as proteolytic enzymes, acting to regulate/process proteins associated with diverse cellular functions. However, the differential expression and altered function of various protease isoforms, such as (i) anti-apoptotic activities, (ii) mediating intercellular adhesion, and (iii) modifying the extracellular matrix, are evidence of their specific contribution towards shaping the tumor microenvironment. Revealing the alternative splicing of protease genes and characterization of their protein products/isoforms with distinct and opposing functions creates a platform to understand how protease isoforms contribute to specific cancer hallmarks. Here, in this review, we address cancer-specific isoforms produced by the alternative splicing of proteases and their distinctive roles in the tumor microenvironment.
Literatur
2.
Zurück zum Zitat Puente, X. S., Ordóñez, G. R., & López-Otín, C. (2008). Protease genomics and the cancer degradome. In G. Høyer-Hansen, D. Edwards, F. Blasi, & B. F. Sloane (Eds.), The cancer degradome (pp. 3–15). New York: Springer.CrossRef Puente, X. S., Ordóñez, G. R., & López-Otín, C. (2008). Protease genomics and the cancer degradome. In G. Høyer-Hansen, D. Edwards, F. Blasi, & B. F. Sloane (Eds.), The cancer degradome (pp. 3–15). New York: Springer.CrossRef
5.
Zurück zum Zitat Buo, L., Aasen, A. O., Karlsrud, T. S., Johansen, H. T., & Sivertsen, S. M. (1990). The role of proteases in the growth, invasion and spread of cancer cells. Tidsskrift for den Norske Lægeforening, 110(29), 3753–3756.PubMed Buo, L., Aasen, A. O., Karlsrud, T. S., Johansen, H. T., & Sivertsen, S. M. (1990). The role of proteases in the growth, invasion and spread of cancer cells. Tidsskrift for den Norske Lægeforening, 110(29), 3753–3756.PubMed
6.
Zurück zum Zitat Duffy, M. J. (1992). The role of proteolytic enzymes in cancer invasion and metastasis. Clinical & Experimental Metastasis, 10(3), 145–155.CrossRef Duffy, M. J. (1992). The role of proteolytic enzymes in cancer invasion and metastasis. Clinical & Experimental Metastasis, 10(3), 145–155.CrossRef
8.
Zurück zum Zitat Zucker, S. (1988). A critical appraisal of the role of proteolytic enzymes in cancer invasion: emphasis on tumor surface proteinases. Cancer Investigation, 6(2), 219–231.PubMedCrossRef Zucker, S. (1988). A critical appraisal of the role of proteolytic enzymes in cancer invasion: emphasis on tumor surface proteinases. Cancer Investigation, 6(2), 219–231.PubMedCrossRef
9.
Zurück zum Zitat Yang, Y., Hong, H., Zhang, Y., & Cai, W. (2009). Molecular imaging of proteases in cancer. Cancer Growth Metastasis, 2, 13–27.PubMedCrossRef Yang, Y., Hong, H., Zhang, Y., & Cai, W. (2009). Molecular imaging of proteases in cancer. Cancer Growth Metastasis, 2, 13–27.PubMedCrossRef
19.
Zurück zum Zitat Webber, M. M., Waghray, A., & Bello, D. (1995). Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clinical Cancer Research, 1(10), 1089–1094.PubMed Webber, M. M., Waghray, A., & Bello, D. (1995). Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clinical Cancer Research, 1(10), 1089–1094.PubMed
23.
Zurück zum Zitat Heuze, N., Olayat, S., Gutman, N., Zani, M. L., & Courty, Y. (1999). Molecular cloning and expression of an alternative hKLK3 transcript coding for a variant protein of prostate-specific antigen. Cancer Research, 59(12), 2820–2824.PubMed Heuze, N., Olayat, S., Gutman, N., Zani, M. L., & Courty, Y. (1999). Molecular cloning and expression of an alternative hKLK3 transcript coding for a variant protein of prostate-specific antigen. Cancer Research, 59(12), 2820–2824.PubMed
24.
Zurück zum Zitat Whitbread, A. K., Veveris-Lowe, T. L., Dong, Y., Tan, O. L., Gardiner, R., Samaratunga, H. M., et al. (2010). Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells. Biological Chemistry, 391(4), 461–466. https://doi.org/10.1515/BC.2010.043.CrossRefPubMed Whitbread, A. K., Veveris-Lowe, T. L., Dong, Y., Tan, O. L., Gardiner, R., Samaratunga, H. M., et al. (2010). Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells. Biological Chemistry, 391(4), 461–466. https://​doi.​org/​10.​1515/​BC.​2010.​043.CrossRefPubMed
25.
Zurück zum Zitat Tanaka, T., Isono, T., Yoshiki, T., Yuasa, T., & Okada, Y. (2000). A novel form of prostate-specific antigen transcript produced by alternative splicing. Cancer Research, 60(1), 56–59.PubMed Tanaka, T., Isono, T., Yoshiki, T., Yuasa, T., & Okada, Y. (2000). A novel form of prostate-specific antigen transcript produced by alternative splicing. Cancer Research, 60(1), 56–59.PubMed
28.
36.
Zurück zum Zitat Magklara, A., Scorilas, A., Katsaros, D., Massobrio, M., Yousef, G. M., Fracchioli, S., et al. (2001). The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clinical Cancer Research, 7(4), 806–811.PubMed Magklara, A., Scorilas, A., Katsaros, D., Massobrio, M., Yousef, G. M., Fracchioli, S., et al. (2001). The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clinical Cancer Research, 7(4), 806–811.PubMed
40.
Zurück zum Zitat Fujise, N., Nanashim, A., Taniguchi, Y., Matsuo, S., Hatano, K., Matsumoto, Y., et al. (2000). Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer, 27(1), 19–26.PubMedCrossRef Fujise, N., Nanashim, A., Taniguchi, Y., Matsuo, S., Hatano, K., Matsumoto, Y., et al. (2000). Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer, 27(1), 19–26.PubMedCrossRef
41.
Zurück zum Zitat Krueger, S., Haeckel, C., Buehling, F., & Roessner, A. (1999). Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer Research, 59(23), 6010–6014.PubMed Krueger, S., Haeckel, C., Buehling, F., & Roessner, A. (1999). Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer Research, 59(23), 6010–6014.PubMed
42.
Zurück zum Zitat Rempel, S. A., Rosenblum, M. L., Mikkelsen, T., Yan, P. S., Ellis, K. D., Golembieski, W. A., et al. (1994). Cathepsin B expression and localization in glioma progression and invasion. Cancer Research, 54(23), 6027–6031.PubMed Rempel, S. A., Rosenblum, M. L., Mikkelsen, T., Yan, P. S., Ellis, K. D., Golembieski, W. A., et al. (1994). Cathepsin B expression and localization in glioma progression and invasion. Cancer Research, 54(23), 6027–6031.PubMed
48.
Zurück zum Zitat Wu, D., Wang, H. J., Li, Z. N., Wang, L. H., Zheng, F. Y., Jiang, J., et al. (2012). Cathepsin B may be a potential biomarker in cervical cancer. Histology and Histopathology, 27(1), 79–87.PubMed Wu, D., Wang, H. J., Li, Z. N., Wang, L. H., Zheng, F. Y., Jiang, J., et al. (2012). Cathepsin B may be a potential biomarker in cervical cancer. Histology and Histopathology, 27(1), 79–87.PubMed
49.
Zurück zum Zitat Mehtani, S., Gong, Q., Panella, J., Subbiah, S., Peffley, D. M., & Frankfater, A. (1998). In vivo expression of an alternatively spliced human tumor message that encodes a truncated form of cathepsin B. Subcellular distribution of the truncated enzyme in COS cells. The Journal of Biological Chemistry, 273(21), 13236–13244. https://doi.org/10.1074/jbc.273.21.13236.CrossRefPubMed Mehtani, S., Gong, Q., Panella, J., Subbiah, S., Peffley, D. M., & Frankfater, A. (1998). In vivo expression of an alternatively spliced human tumor message that encodes a truncated form of cathepsin B. Subcellular distribution of the truncated enzyme in COS cells. The Journal of Biological Chemistry, 273(21), 13236–13244. https://​doi.​org/​10.​1074/​jbc.​273.​21.​13236.CrossRefPubMed
51.
Zurück zum Zitat Rescheleit, D. K., Rommerskirch, W. J., & Wiederanders, B. (1996). Sequence analysis and distribution of two new human cathepsin L splice variants. FEBS Letters, 394(3), 345–348.PubMedCrossRef Rescheleit, D. K., Rommerskirch, W. J., & Wiederanders, B. (1996). Sequence analysis and distribution of two new human cathepsin L splice variants. FEBS Letters, 394(3), 345–348.PubMedCrossRef
55.
Zurück zum Zitat Chauhan, S. S., Popescu, N. C., Ray, D., Fleischmann, R., Gottesman, M. M., & Troen, B. R. (1993). Cloning, genomic organization, and chromosomal localization of human cathepsin L. The Journal of Biological Chemistry, 268(2), 1039–1045.PubMed Chauhan, S. S., Popescu, N. C., Ray, D., Fleischmann, R., Gottesman, M. M., & Troen, B. R. (1993). Cloning, genomic organization, and chromosomal localization of human cathepsin L. The Journal of Biological Chemistry, 268(2), 1039–1045.PubMed
56.
Zurück zum Zitat Estrov, Z., Thall, P. F., Talpaz, M., Estey, E. H., Kantarjian, H. M., Andreeff, M., et al. (1998). Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood, 92(9), 3090–3097.PubMedCrossRef Estrov, Z., Thall, P. F., Talpaz, M., Estey, E. H., Kantarjian, H. M., Andreeff, M., et al. (1998). Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood, 92(9), 3090–3097.PubMedCrossRef
57.
Zurück zum Zitat Faderl, S., Thall, P. F., Kantarjian, H. M., Talpaz, M., Harris, D., Van, Q., et al. (1999). Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clinical Cancer Research, 5(12), 4041–4047.PubMed Faderl, S., Thall, P. F., Kantarjian, H. M., Talpaz, M., Harris, D., Van, Q., et al. (1999). Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clinical Cancer Research, 5(12), 4041–4047.PubMed
59.
Zurück zum Zitat Kumar, S., White, D. L., Takai, S., Turczynowicz, S., Juttner, C. A., & Hughes, T. P. (1995). Apoptosis regulatory gene NEDD2 maps to human chromosome segment 7q34-35, a region frequently affected in haematological neoplasms. Human Genetics, 95(6), 641–644. https://doi.org/10.1007/bf00209480.CrossRefPubMed Kumar, S., White, D. L., Takai, S., Turczynowicz, S., Juttner, C. A., & Hughes, T. P. (1995). Apoptosis regulatory gene NEDD2 maps to human chromosome segment 7q34-35, a region frequently affected in haematological neoplasms. Human Genetics, 95(6), 641–644. https://​doi.​org/​10.​1007/​bf00209480.CrossRefPubMed
62.
Zurück zum Zitat Droin, N., Beauchemin, M., Solary, E., & Bertrand, R. (2000). Identification of a caspase-2 isoform that behaves as an endogenous inhibitor of the caspase cascade. Cancer Research, 60(24), 7039–7047.PubMed Droin, N., Beauchemin, M., Solary, E., & Bertrand, R. (2000). Identification of a caspase-2 isoform that behaves as an endogenous inhibitor of the caspase cascade. Cancer Research, 60(24), 7039–7047.PubMed
66.
70.
Zurück zum Zitat O’Donovan, N., Crown, J., Stunell, H., Hill, A. D., McDermott, E., O’Higgins, N., et al. (2003). Caspase 3 in breast cancer. Clinical Cancer Research, 9(2), 738–742.PubMed O’Donovan, N., Crown, J., Stunell, H., Hill, A. D., McDermott, E., O’Higgins, N., et al. (2003). Caspase 3 in breast cancer. Clinical Cancer Research, 9(2), 738–742.PubMed
72.
Zurück zum Zitat Woenckhaus, C., Giebel, J., Failing, K., Fenic, I., Dittberner, T., & Poetsch, M. (2003). Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression? The Journal of Pathology, 201(2), 278–287. https://doi.org/10.1002/path.1424.CrossRefPubMed Woenckhaus, C., Giebel, J., Failing, K., Fenic, I., Dittberner, T., & Poetsch, M. (2003). Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression? The Journal of Pathology, 201(2), 278–287. https://​doi.​org/​10.​1002/​path.​1424.CrossRefPubMed
73.
84.
Zurück zum Zitat Chalfant, C. E., Rathman, K., Pinkerman, R. L., Wood, R. E., Obeid, L. M., Ogretmen, B., et al. (2002). De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. The Journal of Biological Chemistry, 277(15), 12587–12595. https://doi.org/10.1074/jbc.M112010200.CrossRefPubMed Chalfant, C. E., Rathman, K., Pinkerman, R. L., Wood, R. E., Obeid, L. M., Ogretmen, B., et al. (2002). De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. The Journal of Biological Chemistry, 277(15), 12587–12595. https://​doi.​org/​10.​1074/​jbc.​M112010200.CrossRefPubMed
86.
87.
Zurück zum Zitat Shultz, J. C., Goehe, R. W., Murudkar, C. S., Wijesinghe, D. S., Mayton, E. K., Massiello, A., et al. (2011). SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells. Molecular Cancer Research, 9(7), 889–900. https://doi.org/10.1158/1541-7786.MCR-11-0061.CrossRefPubMed Shultz, J. C., Goehe, R. W., Murudkar, C. S., Wijesinghe, D. S., Mayton, E. K., Massiello, A., et al. (2011). SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells. Molecular Cancer Research, 9(7), 889–900. https://​doi.​org/​10.​1158/​1541-7786.​MCR-11-0061.CrossRefPubMed
90.
Zurück zum Zitat Zhang, D., Liu, H., Yang, B., Hu, J., & Cheng, Y. (2019). L-securinine inhibits cell growth and metastasis of human androgen-independent prostate cancer DU145 cells via regulating mitochondrial and AGTR1/MEK/ERK/STAT3/PAX2 apoptotic pathways. Bioscience Reports, 39(5). https://doi.org/10.1042/BSR20190469. Zhang, D., Liu, H., Yang, B., Hu, J., & Cheng, Y. (2019). L-securinine inhibits cell growth and metastasis of human androgen-independent prostate cancer DU145 cells via regulating mitochondrial and AGTR1/MEK/ERK/STAT3/PAX2 apoptotic pathways. Bioscience Reports, 39(5). https://​doi.​org/​10.​1042/​BSR20190469.
94.
Zurück zum Zitat Muhlethaler-Mottet, A., Flahaut, M., Bourloud, K. B., Nardou, K., Coulon, A., Liberman, J., et al. (2011). Individual caspase-10 isoforms play distinct and opposing roles in the initiation of death receptor-mediated tumour cell apoptosis. Cell Death & Disease, 2, e125. https://doi.org/10.1038/cddis.2011.8.CrossRef Muhlethaler-Mottet, A., Flahaut, M., Bourloud, K. B., Nardou, K., Coulon, A., Liberman, J., et al. (2011). Individual caspase-10 isoforms play distinct and opposing roles in the initiation of death receptor-mediated tumour cell apoptosis. Cell Death & Disease, 2, e125. https://​doi.​org/​10.​1038/​cddis.​2011.​8.CrossRef
103.
Zurück zum Zitat Duhachek Muggy, S. (2014). Multiple isoforms of ADAM12 in breast cancer: differential regulation of expression and unique roles in cancer progression. Kansas State University, K-State Electronic Theses, Dissertations, and Reports: 2004 Duhachek Muggy, S. (2014). Multiple isoforms of ADAM12 in breast cancer: differential regulation of expression and unique roles in cancer progression. Kansas State University, K-State Electronic Theses, Dissertations, and Reports: 2004
106.
Zurück zum Zitat Carl-McGrath, S., Lendeckel, U., Ebert, M., Roessner, A., & Rocken, C. (2005). The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. International Journal of Oncology, 26(1), 17–24.PubMed Carl-McGrath, S., Lendeckel, U., Ebert, M., Roessner, A., & Rocken, C. (2005). The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. International Journal of Oncology, 26(1), 17–24.PubMed
109.
113.
Zurück zum Zitat Hedstrom, L. (2002). Serine protease mechanism and specificity. Chemical Reviews, 102(12), 4501–4524.PubMedCrossRef Hedstrom, L. (2002). Serine protease mechanism and specificity. Chemical Reviews, 102(12), 4501–4524.PubMedCrossRef
115.
Zurück zum Zitat Borgono, C. A., Michael, I. P., & Diamandis, E. P. (2004). Human tissue kallikreins: physiologic roles and applications in cancer. Molecular Cancer Research, 2(5), 257–280.PubMed Borgono, C. A., Michael, I. P., & Diamandis, E. P. (2004). Human tissue kallikreins: physiologic roles and applications in cancer. Molecular Cancer Research, 2(5), 257–280.PubMed
120.
123.
Zurück zum Zitat Obiezu, C. V., Soosaipillai, A., Jung, K., Stephan, C., Scorilas, A., Howarth, D. H., et al. (2002). Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clinical Chemistry, 48(8), 1232–1240.PubMed Obiezu, C. V., Soosaipillai, A., Jung, K., Stephan, C., Scorilas, A., Howarth, D. H., et al. (2002). Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clinical Chemistry, 48(8), 1232–1240.PubMed
126.
Zurück zum Zitat Obiezu, C. V., & Diamandis, E. P. (2000). An alternatively spliced variant of KLK4 expressed in prostatic tissue. Clinical Biochemistry, 33(7), 599–600.PubMedCrossRef Obiezu, C. V., & Diamandis, E. P. (2000). An alternatively spliced variant of KLK4 expressed in prostatic tissue. Clinical Biochemistry, 33(7), 599–600.PubMedCrossRef
127.
Zurück zum Zitat Dong, Y., Kaushal, A., Bui, L., Chu, S., Fuller, P. J., Nicklin, J., et al. (2001). Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clinical Cancer Research, 7(8), 2363–2371.PubMed Dong, Y., Kaushal, A., Bui, L., Chu, S., Fuller, P. J., Nicklin, J., et al. (2001). Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clinical Cancer Research, 7(8), 2363–2371.PubMed
128.
Zurück zum Zitat Korkmaz, K. S., Korkmaz, C. G., Pretlow, T. G., & Saatcioglu, F. (2001). Distinctly different gene structure of KLK4/KLK-L1/prostase/ARM1 compared with other members of the kallikrein family: intracellular localization, alternative cDNA forms, and Regulation by multiple hormones. DNA and Cell Biology, 20(7), 435–445. https://doi.org/10.1089/104454901750361497.CrossRefPubMed Korkmaz, K. S., Korkmaz, C. G., Pretlow, T. G., & Saatcioglu, F. (2001). Distinctly different gene structure of KLK4/KLK-L1/prostase/ARM1 compared with other members of the kallikrein family: intracellular localization, alternative cDNA forms, and Regulation by multiple hormones. DNA and Cell Biology, 20(7), 435–445. https://​doi.​org/​10.​1089/​1044549017503614​97.CrossRefPubMed
130.
Zurück zum Zitat Veveris-Lowe, T. L., Lawrence, M. G., Collard, R. L., Bui, L., Herington, A. C., Nicol, D. L., et al. (2005). Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocrine-Related Cancer, 12(3), 631–643. https://doi.org/10.1677/erc.1.00958.CrossRefPubMed Veveris-Lowe, T. L., Lawrence, M. G., Collard, R. L., Bui, L., Herington, A. C., Nicol, D. L., et al. (2005). Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocrine-Related Cancer, 12(3), 631–643. https://​doi.​org/​10.​1677/​erc.​1.​00958.CrossRefPubMed
137.
139.
Zurück zum Zitat Jin, H., Nagai, N., Shigemasa, K., Gu, L., Tanimoto, H., Yunokawa, M., et al. (2006). Expression of tumor-associated differentially expressed gene-14 (TADG-14/KLK8) and its protein hK8 in uterine endometria and endometrial carcinomas. Tumour Biology, 27(5), 274–282. https://doi.org/10.1159/000094741.CrossRefPubMed Jin, H., Nagai, N., Shigemasa, K., Gu, L., Tanimoto, H., Yunokawa, M., et al. (2006). Expression of tumor-associated differentially expressed gene-14 (TADG-14/KLK8) and its protein hK8 in uterine endometria and endometrial carcinomas. Tumour Biology, 27(5), 274–282. https://​doi.​org/​10.​1159/​000094741.CrossRefPubMed
141.
Zurück zum Zitat Shigemasa, K., Tian, X., Gu, L., Tanimoto, H., Underwood, L. J., O’Brien, T. J., et al. (2004). Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Oncology Reports, 11(6), 1153–1159.PubMed Shigemasa, K., Tian, X., Gu, L., Tanimoto, H., Underwood, L. J., O’Brien, T. J., et al. (2004). Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Oncology Reports, 11(6), 1153–1159.PubMed
142.
148.
Zurück zum Zitat Kusunoki, T., Nishida, S., Nakano, T., Funasaka, K., Kimoto, S., Murata, K., et al. (1995). Study on cathepsin B activity in human thyroid tumors. Auris Nasus Larynx, 22(1), 43–48.PubMedCrossRef Kusunoki, T., Nishida, S., Nakano, T., Funasaka, K., Kimoto, S., Murata, K., et al. (1995). Study on cathepsin B activity in human thyroid tumors. Auris Nasus Larynx, 22(1), 43–48.PubMedCrossRef
150.
Zurück zum Zitat Yan, S., Sameni, M., & Sloane, B. F. (1998). Cathepsin B and human tumor progression. Biological Chemistry, 379(2), 113–123.PubMed Yan, S., Sameni, M., & Sloane, B. F. (1998). Cathepsin B and human tumor progression. Biological Chemistry, 379(2), 113–123.PubMed
152.
Zurück zum Zitat Berquin, I. M., Ahram, M., & Sloane, B. F. (1997). Exon 2 of human cathepsin B derives from an Alu element. FEBS Letters, 419(1), 121–123.PubMedCrossRef Berquin, I. M., Ahram, M., & Sloane, B. F. (1997). Exon 2 of human cathepsin B derives from an Alu element. FEBS Letters, 419(1), 121–123.PubMedCrossRef
160.
Zurück zum Zitat Chauhan, S. S., Goldstein, L. J., & Gottesman, M. M. (1991). Expression of cathepsin L in human tumors. Cancer Research, 51(5), 1478–1481.PubMed Chauhan, S. S., Goldstein, L. J., & Gottesman, M. M. (1991). Expression of cathepsin L in human tumors. Cancer Research, 51(5), 1478–1481.PubMed
163.
Zurück zum Zitat Colella, R., & Casey, S. F. (2003). Decreased activity of cathepsins L + B and decreased invasive ability of PC3 prostate cancer cells. Biotechnic & Histochemistry, 78(2), 101–108.CrossRef Colella, R., & Casey, S. F. (2003). Decreased activity of cathepsins L + B and decreased invasive ability of PC3 prostate cancer cells. Biotechnic & Histochemistry, 78(2), 101–108.CrossRef
164.
Zurück zum Zitat Laurent-Matha, V., Derocq, D., Prebois, C., Katunuma, N., & Liaudet-Coopman, E. (2006). Processing of human cathepsin D is independent of its catalytic function and auto-activation: involvement of cathepsins L and B. Journal of Biochemistry, 139(3), 363–371. https://doi.org/10.1093/jb.mvj037.CrossRefPubMed Laurent-Matha, V., Derocq, D., Prebois, C., Katunuma, N., & Liaudet-Coopman, E. (2006). Processing of human cathepsin D is independent of its catalytic function and auto-activation: involvement of cathepsins L and B. Journal of Biochemistry, 139(3), 363–371. https://​doi.​org/​10.​1093/​jb.​mvj037.CrossRefPubMed
173.
Zurück zum Zitat Wyllie, A. H. (1997). Apoptosis and carcinogenesis. European Journal of Cell Biology, 73(3), 189–197.PubMed Wyllie, A. H. (1997). Apoptosis and carcinogenesis. European Journal of Cell Biology, 73(3), 189–197.PubMed
181.
Zurück zum Zitat Kumar, S., Kinoshita, M., & Noda, M. (1997). Characterization of a mammalian cell death gene Nedd2. Leukemia, 11(Suppl 3), 385–386.PubMed Kumar, S., Kinoshita, M., & Noda, M. (1997). Characterization of a mammalian cell death gene Nedd2. Leukemia, 11(Suppl 3), 385–386.PubMed
184.
198.
203.
205.
Zurück zum Zitat Srinivasula, S. M., Ahmad, M., Guo, Y., Zhan, Y., Lazebnik, Y., Fernandes-Alnemri, T., et al. (1999). Identification of an endogenous dominant-negative short isoform of caspase-9 that can regulate apoptosis. Cancer Research, 59(5), 999–1002.PubMed Srinivasula, S. M., Ahmad, M., Guo, Y., Zhan, Y., Lazebnik, Y., Fernandes-Alnemri, T., et al. (1999). Identification of an endogenous dominant-negative short isoform of caspase-9 that can regulate apoptosis. Cancer Research, 59(5), 999–1002.PubMed
208.
Zurück zum Zitat Harada, K., Toyooka, S., Shivapurkar, N., Maitra, A., Reddy, J. L., Matta, H., et al. (2002). Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Research, 62(20), 5897–5901.PubMed Harada, K., Toyooka, S., Shivapurkar, N., Maitra, A., Reddy, J. L., Matta, H., et al. (2002). Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Research, 62(20), 5897–5901.PubMed
215.
Zurück zum Zitat Stone, A. L., Kroeger, M., & Sang, Q. X. (1999). Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase-containing proteins (review). Journal of Protein Chemistry, 18(4), 447–465.PubMedCrossRef Stone, A. L., Kroeger, M., & Sang, Q. X. (1999). Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase-containing proteins (review). Journal of Protein Chemistry, 18(4), 447–465.PubMedCrossRef
224.
Zurück zum Zitat Kodama, T., Ikeda, E., Okada, A., Ohtsuka, T., Shimoda, M., Shiomi, T., et al. (2004). ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. American Journal of Pathology, 165(5), 1743–1753. https://doi.org/10.1016/S0002-9440(10)63429-3.CrossRef Kodama, T., Ikeda, E., Okada, A., Ohtsuka, T., Shimoda, M., Shiomi, T., et al. (2004). ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. American Journal of Pathology, 165(5), 1743–1753. https://​doi.​org/​10.​1016/​S0002-9440(10)63429-3.CrossRef
226.
Zurück zum Zitat Mino, N., Miyahara, R., Nakayama, E., Takahashi, T., Takahashi, A., Iwakiri, S., et al. (2009). A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma. Journal of Surgical Oncology, 100(3), 267–272. https://doi.org/10.1002/jso.21313.CrossRefPubMed Mino, N., Miyahara, R., Nakayama, E., Takahashi, T., Takahashi, A., Iwakiri, S., et al. (2009). A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma. Journal of Surgical Oncology, 100(3), 267–272. https://​doi.​org/​10.​1002/​jso.​21313.CrossRefPubMed
227.
Zurück zum Zitat Narita, D., Anghel, A., Seclaman, E., Ilina, R., Cireap, N., & Ursoniu, S. (2010). Molecular profiling of ADAM12 gene in breast cancers. Romanian Journal of Morphology and Embryology, 51(4), 669–676.PubMed Narita, D., Anghel, A., Seclaman, E., Ilina, R., Cireap, N., & Ursoniu, S. (2010). Molecular profiling of ADAM12 gene in breast cancers. Romanian Journal of Morphology and Embryology, 51(4), 669–676.PubMed
235.
Zurück zum Zitat Frohlich, C., Klitgaard, M., Noer, J. B., Kotzsch, A., Nehammer, C., Kronqvist, P., et al. (2013). ADAM12 is expressed in the tumour vasculature and mediates ectodomain shedding of several membrane-anchored endothelial proteins. Biochemical Journal, 452, 97–109. https://doi.org/10.1042/Bj20121558.CrossRef Frohlich, C., Klitgaard, M., Noer, J. B., Kotzsch, A., Nehammer, C., Kronqvist, P., et al. (2013). ADAM12 is expressed in the tumour vasculature and mediates ectodomain shedding of several membrane-anchored endothelial proteins. Biochemical Journal, 452, 97–109. https://​doi.​org/​10.​1042/​Bj20121558.CrossRef
238.
Zurück zum Zitat Kang, Q., Cao, Y., & Zolkiewska, A. (2000). Metalloprotease-disintegrin ADAM 12 binds to the SH3 domain of Src and activates Src tyrosine kinase in C2C12 cells. Biochemical Journal, 352(Pt 3), 883–892.PubMedCentral Kang, Q., Cao, Y., & Zolkiewska, A. (2000). Metalloprotease-disintegrin ADAM 12 binds to the SH3 domain of Src and activates Src tyrosine kinase in C2C12 cells. Biochemical Journal, 352(Pt 3), 883–892.PubMedCentral
242.
243.
Zurück zum Zitat Nath, D., Slocombe, P. M., Stephens, P. E., Warn, A., Hutchinson, G. R., Yamada, K. M., et al. (1999). Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. Journal of Cell Science, 112(Pt 4), 579–587.PubMed Nath, D., Slocombe, P. M., Stephens, P. E., Warn, A., Hutchinson, G. R., Yamada, K. M., et al. (1999). Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. Journal of Cell Science, 112(Pt 4), 579–587.PubMed
244.
Zurück zum Zitat Eto, K., Puzon-McLaughlin, W., Sheppard, D., Sehara-Fujisawa, A., Zhang, X. P., & Takada, Y. (2000). RGD-independent binding of integrin alpha9beta1 to the ADAM-12 and -15 disintegrin domains mediates cell-cell interaction. The Journal of Biological Chemistry, 275(45), 34922–34930. https://doi.org/10.1074/jbc.M001953200.CrossRefPubMed Eto, K., Puzon-McLaughlin, W., Sheppard, D., Sehara-Fujisawa, A., Zhang, X. P., & Takada, Y. (2000). RGD-independent binding of integrin alpha9beta1 to the ADAM-12 and -15 disintegrin domains mediates cell-cell interaction. The Journal of Biological Chemistry, 275(45), 34922–34930. https://​doi.​org/​10.​1074/​jbc.​M001953200.CrossRefPubMed
247.
Zurück zum Zitat Wotawa, A., Solier, S., Logette, E., Solary, E., & Corcos, L. (2002). Differential influence of etoposide on two caspase-2 mRNA isoforms in leukemic cells. Cancer Letters, 185(2), 181–189.PubMedCrossRef Wotawa, A., Solier, S., Logette, E., Solary, E., & Corcos, L. (2002). Differential influence of etoposide on two caspase-2 mRNA isoforms in leukemic cells. Cancer Letters, 185(2), 181–189.PubMedCrossRef
248.
Zurück zum Zitat Solier, S., Lansiaux, A., Logette, E., Wu, J., Soret, J., Tazi, J., et al. (2004). Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Molecular Cancer Research, 2(1), 53–61.PubMed Solier, S., Lansiaux, A., Logette, E., Wu, J., Soret, J., Tazi, J., et al. (2004). Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Molecular Cancer Research, 2(1), 53–61.PubMed
Metadaten
Titel
Differential roles of protease isoforms in the tumor microenvironment
verfasst von
Chamikara Liyanage
Achala Fernando
Jyotsna Batra
Publikationsdatum
31.10.2019
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 3/2019
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-019-09816-2

Weitere Artikel der Ausgabe 3/2019

Cancer and Metastasis Reviews 3/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.